This pharmaceutical business received approval to build a new plant to manufacture its well-known medicine 'Ibuprofen'

This pharmaceutical business received approval to build a new plant to manufacture its well-known medicine 'Ibuprofen'

by 5paisa Research Team Last Updated: Dec 13, 2022 - 09:48 am 11.4k Views
Listen icon

Solara obtained CEP certification so that its Vishakhapatnam facility may produce ibuprofen.

As of today on the BSE, Solara Active Pharma Sciences is trading at Rs 415.00, up 17.35 points or 4.36% from its previous closing price of Rs 397.65. The stock's opening price was Rs 397.40, and it has since reached highs of Rs 419.65 and lows of Rs 392.45. Today, 10241 shares have been traded thus far on the counter. The 52-week high of Rs 1385.00 was reached on November 10, 2021, and a 52-week low of Rs 323.65 was reached on June 20, 2022.

The European Directorate for the Quality of Medicines (EDQM) has granted Solara Active Pharma Sciences (Solara) the first worldwide regulatory licence for its brand-new, cutting-edge, multipurpose API manufacturing plant in Vishakhapatnam, Andhra Pradesh, for the production of Ibuprofen API.

With this crucial certification, Solara now has CEP permission for two Ibuprofen API manufacturing plants, the other of which is a dedicated site in Puducherry, India. For its Vizag facility, Solara also anticipates receiving a number of other foreign regulatory clearances, including the USFDA.

The business is a global, R&D-focused, pure-play Active Pharmaceutical Ingredients (API) manufacturer and developer that also provides contract manufacturing and development services to other international businesses. The company currently has more than 60 commercial APIs and more than 10 APIs in development in high-value product sectors. The company keeps putting its emphasis on expanding its customer base for high-volume products, CIPs, and backward integration. It also emphasises finding new markets for current items and developing tools for more tightly controlled market sales.

The company's sales in Q1FY23 were Rs 330 crore. In the June quarter, the operating profit was Rs 4 crore.

The promoters' ownership stake in the company was 40.40%, compared to institutions' 21.44% and noninstitutional 38.16%.

Share Market Today

How do you rate this article?

Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage


About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.


Investment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial.
Open Free Demat Account
Resend OTP
Please Enter OTP
Mobile No. belongs to

By proceeding, you agree to the T&C.

Latest News
What you must know about M.V.K. Agro Food IPO?

M.V.K. Agro Food Product IPO was incorporated in the year 2018 to manufacture integrated sugar and other related products. M.V.K.

Juniper Hotels IPO Subscribed 2.08 times

The stock of Juniper Hotels IPO has a face value of ₹10 per share and the price band for the book building IPO has been set in the range of ₹342 to ₹360 per share. The IPO of Juniper Hotels Ltd will entirely a fresh issue of shares with no offer for sale (OFS) component.

Esconet Technologies IPO Lists 245.24% higher, but closes at -5% lower circuit

Bumper listing for Esconet Technologies IPO, then lower circuit